Ranitidine
- CAS No.
- 66357-35-5
- Chemical Name:
- Ranitidine
- Synonyms
- RANITIDINE BASE;Ranitidin;Trigger;RANITIDINE USP;RND;U1cex;Taural;Zantae;Zantic;Sampep
- CBNumber:
- CB5480252
- Molecular Formula:
- C13H22N4O3S
- Molecular Weight:
- 314.4
- MDL Number:
- MFCD00081180
- MOL File:
- 66357-35-5.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Product description | Number | Pack Size | Price |
| Ranitidine | R0261 | 1G | $112 |
| Ranitidine | R0261 | 5G | $388 |
| N-[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine ≥98% | AA0035HJ | 5g | $10 |
| N-[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine ≥98% | AA0035HJ | 25g | $17 |
| N-[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine ≥98% | AA0035HJ | 100g | $61 |
| More product size | |||
| Melting point | 69-70°C |
|---|---|
| Boiling point | 437.1±45.0 °C(Predicted) |
| Density | 1.184±0.06 g/cm3(Predicted) |
| storage temp. | Desiccate at +4°C |
| solubility | H2O: 1.8 mg/mL |
| pka | pKa 2.19±0.04 (Uncertain) |
| form | solid |
| color | tan |
| Water Solubility | 24.7 mg/mL |
| Stability | Hygroscopic |
| CAS DataBase Reference | 66357-35-5(CAS DataBase Reference) |
| NCI Dictionary of Cancer Terms | trigger |
| FDA UNII | 884KT10YB7 |
| NCI Drug Dictionary | ranitidine hydrochloride |
| ATC code | A02BA02 |
| NIST Chemistry Reference | Ranitidine(66357-35-5) |
| EPA Substance Registry System | 1,1-Ethenediamine, N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro- (66357-35-5) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|---|---|
| Signal word | Warning |
| Hazard statements | H315-H319 |
| Precautionary statements | P264-P280-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362 |
| Safety Statements | 22-24/25 |
| WGK Germany | 2 |
| RTECS | KM6557000 |
| Hazardous Substances Data | 66357-35-5(Hazardous Substances Data) |
| Toxicity | LD50 oral in rat: > 5gm/kg |
| REACH Registrations | Active |
Ranitidine price More Price(24)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| TCI Chemical | R0261 | Ranitidine | 66357-35-5 | 1G | $112 | 2026-04-30 | Buy |
| TCI Chemical | R0261 | Ranitidine | 66357-35-5 | 5G | $388 | 2026-04-30 | Buy |
| aablocks | AA0035HJ | N-[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine ≥98% | 66357-35-5 | 5g | $10 | 2026-05-28 | Buy |
| aablocks | AA0035HJ | N-[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine ≥98% | 66357-35-5 | 25g | $17 | 2026-05-28 | Buy |
| aablocks | AA0035HJ | N-[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-1,1-ethenediamine ≥98% | 66357-35-5 | 100g | $61 | 2026-05-28 | Buy |
Ranitidine Chemical Properties,Uses,Production
Description
Ranitidine, a H2-receptor agonist, caused contact dermatitis within the pharmaceutical industry.
History
Ranitidine was first prepared in England as AH19065 by John Bradshaw in the summer of 1977 in the Ware research laboratories of Allen and Hanburys, part of the former Glaxo organisation.Glaxo refined the model further, by replacing the imidazole ring of cimetidine with a furan ring with a nitrogen-containing substituent, and in doing so developed ranitidine. Ranitidine was found to have a far-improved tolerability profile (i.e. fewer adverse drug reactions), longer-lasting action, and 10 times the activity of cimetidine.
Ranitidine was introduced in 1981, and was the world's biggest-selling prescription drug by 1987. Subsequently, it was largely superseded by the more effective proton-pump inhibitor (PPI) class of drugs, with omeprazole becoming the biggest-selling drug for many years.
In September 2019, the probable carcinogen N-nitrosodimethylamine (NDMA) was discovered in ranitidine products from a number of manufacturers, resulting in recalls; in April 2020, it was withdrawn from the United States market and suspended in Europe and Australia. In 2024, ranitidine was re-approved for sale in Australia after the local sponsor of Zantac changed suppliers and tablet formulation. The new formulation was demonstrated to be stable throughout its shelf life and that nitrosamines are controlled within internationally established acceptable intake limits applied to the maximum daily dose.
Uses
Antagonist (to histamine H2receptors).
Uses
It simultaneously reduces pepsin activity and is used for treating stomach and duodenum ulcers as well as other conditions accompanied by elevated acidity of the gastrointestinal tract. Synonyms of this drug are zantac, azantac, raniplex, ranidil, and others.
Uses
Ranitidine (cas# 66357-35-5) was used as a standard for testing the therapeutic effect of brown propolis extract against aspirin and ethanol- induced gastric ulcers.
Indications
Ranitidine (Zantac) is another H2 receptor antagonist that does not have the same antiandrogen side effects as cimetidine. Note that both cimetidine and ranitidine inhibit the cytochrome P-450 microsomal enzyme system.
Definition
ChEBI: Ranitidine is a member of the class of furans used to treat peptic ulcer disease (PUD) and gastroesophageal reflux disease. It has a role as an anti-ulcer drug, a H2-receptor antagonist, an environmental contaminant, a xenobiotic and a drug allergen. It is a member of furans, a tertiary amino compound, a C-nitro compound and an organic sulfide.
brand name
Zantac (GlaxoSmithKline).
General Description
Ranitidine, N-[2-[[[5-(dimethylamino)methyl]-2-furanyl]methyl]thiol] ethyl]-N'-methyl-2-nitro-l,1-ethenediamine (Zantac), is a white solid, which inits hydrochloride salt form is highly soluble in water. It is anaminoalkyl furan derivative with pKa values of 2.7 (sidechain) and 8.2 (dimethylamino). Ranitidine is more potentthan cimetidine, but less potent than famotidine. Likeother H2-antagonists, it does not appear to bind to otherreceptors.
Bioavailability of an oral dose of ranitidine is about 50%and is not significantly affected by the presence of food.Some antacids may reduce ranitidine absorption and shouldnot be taken within 1 hour of administration of this drug. Theplasma half-life of the drug is 2 to 3 hours, and it is excretedalong with its metabolites in the urine. Three metabolites, ranitidineN-oxide, ranitidine S-oxide, and desmethyl ranitidine,have been identified. Ranitidine is only a weak inhibitor ofthe hepatic cytochrome isozymes, and recommended doses ofthe drug do not appear to inhibit the metabolism of otherdrugs. However, there have been isolated reports of drug interactions(warfarin, triazolam) that suggest that ranitidinemay affect the bioavailability of certain drugs by someunidentified mechanism, perhaps by pH-dependent effect onabsorption or a change in volume of distribution.
In addition to being available in various dosage forms asthe hydrochloride salt, ranitidine is also available as a bismuthcitrate salt for use with the macrolide antibiotic clarithromycinin treating patients with an active duodenalulcer associated with H. pylori infection. Eradication of H.pylori reduces the risk of duodenal ulcer recurrence.
Biological Activity
Potent, selective and competitive histamine H 2 receptor antagonist (pA 2 = 6.95-7.2). In vivo, inhibits gastric acid secretion induced by histamine, pentagastrin, bethanecol and food. Also inhibits aspirin-induced gastric lesions.
Contact allergens
Ranitidine, an H2-receptor antagonist, can cause contact dermatitis within the pharmaceutical industry and in health care workers, or may induce systemic drug reactions in patients.
Clinical Use
H2
antagonist:
Conditions associated with hyperacidity
Synthesis
Ranitidine, N[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]- N-methyl-2-nitro-1,1-ethendiamine (16.2.8), is synthesized from furfuryl alcohol, which undergoes aminomethylation reaction using dimethylamine and paraform, which form 5- (dimethylaminomethyl)furfuryl alcohol (16.2.6). Further reaction with 2-mercaptoethylamine hydrochloride gives a product of substitution of the hydroxyl group in (16.2.6), 5-dimethylaminomethyl-2-(2-aminoethyl)thiomethylfurane (16.2.7). Reacting this with Nmethyl- 1-methylthio-2-nitroethenaamine gives ranitidine (16.2.8).
Drug interactions
Potentially hazardous interactions with other drugs
Alpha-blockers: effects of tolazoline antagonised.
Antifungals: absorption of itraconazole and
ketoconazole reduced; concentration of posaconazole
possibly reduced - avoid.
Antivirals: concentration of atazanavir reduced;
concentration of raltegravir possibly increased - avoid;
avoid for 12 hours before and 4 hours after rilpivirine.
Ciclosporin: may increase or not change ciclosporin
levels; nephrotoxicity, additive hepatotoxicity and
thrombocytopenia reported.
Cytotoxics: reduced gefitinib concentration; reduces
concentration of erlotinib and possibly pazopanib,
give at least 2 hours before or 10 hours after
ranitidine; absorption of dasatinib reduced - avoid;
possibly reduced absorption of lapatinib.
Ulipristal: contraceptive effect possibly reduced -
avoid with high dose ulipristal.
Metabolism
Ranitidine is not extensively metabolised. A small
proportion of ranitidine is metabolised in the liver to
the N-oxide, the S-oxide, and desmethylranitidine; the
N-oxide is the major metabolite but accounts for only
about 4-6% of a dose.
The fraction of the dose recovered as metabolites is
similar after both oral and IV dosing; and includes 6%
of the dose in urine as the N-oxide, 2% as the S-oxide,
2% as desmethylranitidine and 1-2% as the furoic acid
analogue. There is also some excretion in the faeces.
Dosage forms
150 mg b.i.d.
Ranitidine Preparation Products And Raw materials
Raw materials
1of3
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shaanxi TNJONE Pharmaceutical Co., Ltd | +8618092446649 | sarah@tnjone.com | China | 1143 | 58 |
| Henan Suikang Pharmaceutical Co.,Ltd. | +86-18239973690 | sales@suikangpharm.com | China | 311 | 58 |
| Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 | info@tianfuchem.com | China | 21588 | 55 |
| career henan chemical co | +86-0371-86658258 +8613203830695 | sales@coreychem.com | China | 29815 | 58 |
| Xiamen AmoyChem Co., Ltd | +86-86-5926051114 +8615060885618 | sales@amoychem.com | China | 6366 | 58 |
| Shenzhen Excellent Biotech Co., Ltd. | 13480692018 | ramyan@ex-biotech.com | CHINA | 954 | 58 |
| CONIER CHEM AND PHARMA LIMITED | +8618523575427 | sales@conier.com | China | 49979 | 58 |
| Neostar United (Changzhou) Industrial Co., Ltd. | +86-0519-85551759 +8613506123987 | marketing1@neostarunited.com | China | 8828 | 58 |
| SIMAGCHEM CORP | +86-5922680277 +86-13806087780 | sale@simagchem.com | China | 17346 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +17819995354 | marketing@targetmol.com | United States | 32466 | 58 |
View Lastest Price from Ranitidine manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-05-29 | Ranitidine
66357-35-5
|
$40.00-98.00 | 99.56% | 10g | TargetMol Chemicals Inc. | ||
 |
2025-04-15 | Ranitidine
66357-35-5
|
1kg | 99.0% | 1tons | Henan Suikang Pharmaceutical Co.,Ltd. | ||
 |
2025-04-02 | Ranitidine
66357-35-5
|
1kg | 99% | 20tons | Shaanxi TNJONE Pharmaceutical Co., Ltd |
-
- Ranitidine
66357-35-5
- $40.00-98.00
- 99.56%
- TargetMol Chemicals Inc.
-
- Ranitidine
66357-35-5
- 99.0%
- Henan Suikang Pharmaceutical Co.,Ltd.
-
- Ranitidine
66357-35-5
- $0.00
- 99%
- Shaanxi TNJONE Pharmaceutical Co., Ltd
66357-35-5(Ranitidine)Related Search:
1of3
